

# Coding Guide for ABRYSSVO™ Administration



**ABRYSSVO™ (Respiratory Syncytial Virus Vaccine) was approved by the Food & Drug Administration on May 31, 2023.<sup>1</sup>**  
**ABRYSSVO™ is billable using the CPT® code 90678<sup>2</sup>**

<b>ABRYSSVO™ CPT® code<sup>2</sup></b>	<b>90678</b> (Respiratory Syncytial Virus vaccine, preF, subunit, bivalent, for intramuscular use)	
<b>Diagnosis Code (ICD-10-CM)<sup>3*</sup></b>	<b>Z23</b> (Encounter for immunization)	
<b>MVX Code<sup>4</sup></b>	<b>PFR</b>	
<b>CVX Code<sup>5</sup></b>	<b>305</b>	
<b>Unit of Use (11-digit NDC Number)<sup>6</sup></b>	<b>00069-0207-01</b>	ABRYSSVO™ single dose vial
<b>Units of Sale (11-digit NDC Number)<sup>6</sup></b>	<b>00069-0344-01</b>	0.5 mL solution for intramuscular injection, 1-dose carton (2 mL vial, 1 mL prefilled syringe, vial adapter)
	<b>00069-0344-05</b>	0.5 mL solution for intramuscular injection, 5-dose carton
<b>Billing codes for administration</b>	<b>90471</b> Immunization administration (includes percutaneous, intradermal, subcutaneous or intramuscular injection(s); one vaccine (single or combination vaccine/toxoid) <sup>2</sup>	
	<b>Medicare Part B administration code modifier: GY<sup>2,7†</sup></b>	

\*This code indicates an encounter for immunization and is reported for all vaccines given within an encounter.<sup>3</sup>

†A GY modifier must be used when physicians, practitioners, or suppliers want to indicate that the item or service is statutorily non-covered or is not a Medicare benefit.<sup>7</sup>

CPT = Current Procedural Terminology; ICD-10 = International Classification of Diseases, 10th Revision; NDC = National Drug Code.

## INDICATION

ABRYSSVO is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.

## IMPORTANT SAFETY INFORMATION (continued on next page)

- Do not administer ABRYSSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSSVO
- Appropriate medical treatment must be available in case of an anaphylactic reaction
- Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSSVO. Procedures should be in place to avoid injury from fainting

Please see [full Prescribing Information](#) for ABRYSSVO.

# ABRYSSVO™ Is Covered Under Medicare Part D



## For populating specific fields of the CMS-1500 (physician office) or CMS-1450/UB-04 (hospital outpatient department) claim forms

Information Requested	Enter this information	CMS-1500 Item Number	CMS-1450 Item Number
<b>Medication Information<sup>2</sup></b>			
ABRYSSVO™ CPT® Code	<b>90678</b>	24D	FL44
• Full name of medication, dosage, basis of management	<b>ABRYSSVO™, 0.5 mL</b>	19/24A shaded area	FL43
<b>Diagnosis Information<sup>2,3</sup></b>			
ICD-10-CM code	<b>Z23</b>	21*	FL 67
<b>Electronic Data Exchange Format<sup>2</sup></b>			
ABRYSSVO™ single dose vial	<b>N400069020701 mL0.5</b>	24G (place code in shaded area at the top of the line)	FL 43
<b>Administration code</b>			
• Medicare <sup>2,7</sup>	<b>90471<sup>†</sup></b>	24D	FL44
• Commercial <sup>2</sup>	<b>90471</b>		

\*Enter the ICD indicator "0" in item 21 for CMS-1500.

†A GY modifier must be used when physicians, practitioners, or suppliers want to indicate that the item or service is statutorily non-covered or is not a Medicare benefit.<sup>7</sup>

CPT = Current Procedural Terminology; ICD-10 = International Classification of Diseases, tenth revision; NDC = National Drug Code.

### IMPORTANT SAFETY INFORMATION (continued)

- Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSSVO
- Vaccination with ABRYSSVO may not protect all vaccine recipients
- In clinical trials, the most commonly reported ( $\geq 10\%$ ) adverse reactions were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%)

### Please see [full Prescribing Information for ABRYSSVO](#).

1. Food and Drug Administration. Approval of ABRYSSVO™. Updated May 31, 2023. Accessed June 5, 2023. <https://www.fda.gov/media/168890/download> 2. Data on file, Pfizer Inc, 2023. 3. Taylor BA. Coding corner: vaccine sticking points. Updated July 2017. Accessed June 5, 2023. <https://www.fortherecordmag.com/archives/0717p28.shtml> 4. Centers for Disease Control and Prevention. Immunization information systems (IIS). Updated March 21, 2023. Accessed May 11, 2023. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=mxv> 5. Centers for Disease Control and Prevention. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. [https://www2a.cdc.gov/vaccines/iis/iisstandards/downloads/cvx\\_list.pdf](https://www2a.cdc.gov/vaccines/iis/iisstandards/downloads/cvx_list.pdf) 6. Abryssvo™ Prescribing Information. Pfizer Inc., 2023. 7. Centers for Medicare and Medicaid Services. CMS Manual System. February 2011. Accessed June 5, 2023. <https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/r2148cp.pdf>